4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0001193125-25-308354
Chief Executive Officer sold 79,973 shares at an average $145.66 ($11,648,582)
- Chief Executive Officer acquired 79,973 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
TABUTEAU HERRIOT · Chief Executive Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-12-02 | Exercise or conversion : show line 1 in the form 10b5-1 | +49,252 | $8.02 | $395,001 | 56,481 | D |
| 2025-12-02 | Sale : show line 2 in the form 10b5-1 | −49,252 | $144.59 | $7,121,347 | 7,229 | D |
| 2025-12-03 | Exercise or conversion : show line 3 in the form 10b5-1 | +20,163 | $8.02 | $161,707 | 27,392 | D |
| 2025-12-03 | Sale : show line 4 in the form 10b5-1 | −20,163 | $146.94 | $2,962,751 | 7,229 | D |
| 2025-12-04 | Exercise or conversion : show line 5 in the form 10b5-1 | +10,558 | $8.02 | $84,675 | 17,787 | D |
| 2025-12-04 | Sale : show line 6 in the form 10b5-1 | −10,558 | $148.18 | $1,564,484 | 7,229 | D |
| Open-market sales · 79,973 sh · avg $145.66 · $11,648,582 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-12-02 | Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) | −49,252 | 202,545 | D |
| 2025-12-03 | Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) | −20,163 | 182,382 | D |
| 2025-12-04 | Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (Right to Buy) | −10,558 | 171,824 | D |
Loading xslF345X05/ownership.xml…